Effect of Carrilizumab Combined with Chemotherapy on Advanced Non-squamous Non-small Cell Lung Cancer
Objective:To investigate the effect of Carrilizumab combined with chemotherapy on advanced non-squamous non-small cell lung cancer(NSCLC).Method:A total of 60 patients with advanced non-squamous NSCLC admitted to Zhongshan Chenxinghai Hospital of Integrated Traditional Chinese and Western Medicine from May 2022 to May 2023 were selected.They were randomly divided into Carrilizumab group(n=30)and chemotherapy treatment group(n=30).The chemotherapy treatment group was given chemotherapy,and the Carrilizumab group was given Carrilizumab on the basis of chemotherapy treatment group.The clinical efficacy,T lymphocyte subsets,quality of life before and after treatment,toxicity and side effects were compared between the two groups.Result:The objective response rate(ORR)in Carrelizumab group was 63.33%,which was higher than 33.33%in chemotherapy treatment group,and the difference was statistically significant(P<0.05).After treatment,CD4+and CD4+/CD8+levels in both groups were increased,and CD4+and CD4+/CD8+levels in Carrilizumab group were higher than those in chemotherapy non-squamous group,while CD8+level was lower than that in chemotherapy treatment group,and the differences were statistically significant(P<0.05).After treatment,the scores of physical function,social function,role function,cognitive function,emotional function and general health status of the two groups were increased,and the scores of physical function,social function,role function,cognitive function,emotional function and general health status of Carrellizumab group were higher than those of the chemotherapy treatment group,and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of toxic and side effects between the two groups(P>0.05).Conclusion:Carrellizumab combined with chemotherapy in the treatment of advanced non-squamous NSCLC has good clinical efficacy,can improve the immune function,improve the quality of life of patients,and has a safety.
CarrilizumabAdvanced non-squamous non-small cell lung cancerImmunity functionPulmonary immunity prognostic index
万方数据
维普
